Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Coenzyme Q10 serum levels in Huntington’s disease

  • Chapter
Focus on Extrapyramidal Dysfunction

Part of the book series: Journal of Neural Transmission. Supplementa ((NEURAL SUPPL,volume 68))

Summary

Summary. Mitochondrial dysfunction contributes to the neurodegenerative process in Huntington’s disease (HO). Coenzyme Q10 (CoQ10) enhances mitochondrial complex I activity and may therefore provide a therapeutic benefit in HD. We compared serum CoQ10 levels of previously untreated — and treated HO patients with those of healthy controls. CoQ10 did not significantly (ANCOVA F(dF2,dF55)= 2.57; p = 0.086) differ between all three groups . However, the post hoc analysis showed no significant (p = 0.4) difference between treated HD patients ([CoQ10]: 88.12 [mean] ± 24.44 [SD], [range] 48.75−146.32 [pg/million platelets]) and controls (93.71 ± 20.72, 65.31−157.94), however previously untreated HD patients (70.10 ± 21.12, 38.67−106.14) had marked (p = 0.051) lower CoQ10 results than treated HO patients and controls (p = 0.017). Our results support that CoQ10 supplementation in HO patients may reduce impaired mitochondrial function in HD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Arenas J, Campos Y, Ribacoba R, Martin MA, Rubio JC, Ablanedo P, Cabello A (1998) Complex I defect in muscle from patients with Huntington’s disease. Ann Neurol 43: 397–400

    Article  PubMed  CAS  Google Scholar 

  • Beal MF (1994) Neurochemistry and toxin models in Huntingtons disease. Curr Opin Neurol 7: 542–547

    Article  PubMed  CAS  Google Scholar 

  • Beal MF (1999) Mitochondria, NO and neurodegeneration. Biochem Soc Symp 66: 43–54

    PubMed  CAS  Google Scholar 

  • Cooper JM, Schapira AH (1997) Mitochondrial dysfunction in neurodegeneration. J Bioenerg Biomembr 29: 175–183

    Google Scholar 

  • Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF (2002) Therapeutic effects of coenzyme Q( 10) and remacemide in transgenic mouse models of Huntington’s disease. J Neurosci 22: 1592–1599

    PubMed  CAS  Google Scholar 

  • Furtado S, Suchowersky O, Rewcastle B, Graham L, Klimek ML, Garber A (1996) Relationship between trinucleotide repeats and neuropathological changes in Huntington’s disease. Ann Neurol 39: 132–136

    Article  PubMed  CAS  Google Scholar 

  • Gotz ME, Gerstner A, Harth R, Dirr A, Janetzky B, Kuhn W, Riederer P, Gerlach M (2000) Altered redox state of platelet coenzyme Q(10) in Parkinson’s disease. J Neural Transm 107: 41–48

    Article  PubMed  CAS  Google Scholar 

  • Gu M, Gash MT, Mann VM, JavoyAgid F, Cooper JM, Schapira AHV (1996) Mitochondrial defect in Huntington’ s disease on caudate nucleus. Ann Neurol 39: 385–389

    Article  PubMed  CAS  Google Scholar 

  • Huntington Study Group (1996) Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord 11: 136–142

    Article  Google Scholar 

  • Kasparova S, Sumbalova Z, Kucharska J, Bystricky P, Mlynarik V, Gvozdjakova A (2002) Effect of coenzyme Q(10) on energy metabolism in aged rats with Huntington’s disease. J Mol Cell Cardiol 34: A84

    Google Scholar 

  • Keene CD, Rodrigues CMP, Eich T, Linehan-Stieers C, Abt A, Kren BT, Steer CJ, Low WC (2001) A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington’s disease. Exp Neurol 171: 351–360

    Article  PubMed  CAS  Google Scholar 

  • Kieburtz K, Koroshetz W, McDennott M, Beal MF, Greenamyre JT, Ross CA, Shoulson I, Cudkowicz ME, Sexton P, Skeuse C, Rosas D, Jenkins B, Rosenblatt A, Sherr M, Hersch S, Cellar J, Guttman M, Brown C, Como PG, Marshall F, DeMarcaida JA, Zimmennan C, Marder K, Moskowitz C, Polanco C, Beltre J, Shannon K, Jaglin JA, Niederman F, Ashizawa T Hunter C, Hunter C, Hauser R, Walker A, Gauger L, Hahn MA, Delgado H, Dawson T, Siemers E, Seeberger L, Dingmann C, Dubinsky R, Gray C, Weiner WJ, Rodriguez-Batemen D, Albin RL, Wernette K, Harrison M, Rost-Ruffner E, Paulsen J, Rodnitzky RL, Dobson J, Vining L, Suchowersky O, Pantella C, Saint-Hilaire MH, Furtado J, Martin W, Wieler M, Walker F, Hunt V, Raymond L, Almqvist E, Rubin A, Blair B, Marek K, Caplan K, Baker D, Brocht A, Casaceli C, Onne C, Rudolph A, Rumfola L, Schifitto G, Shinaman A, Sulimowicz K, Watts A, Eapen S, Zhang L (2001) A randomized, placebo-controlled trial of coenzyme Q(IO) and remacemide in Huntington’s disease. Neurology 57: 397–404

    CAS  Google Scholar 

  • Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF (1997) Energy metabolism defects in Huntington’s disease and effects of coenzyme Q(10). Ann Neurol 41: 160–165

    Article  PubMed  CAS  Google Scholar 

  • Matthews RT, Yang L, Browne S, Baik M, Beal MF (1998) Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA 95: 8892–8897

    Article  PubMed  CAS  Google Scholar 

  • Maurer I, Moller HJ (1997) Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol Cell Biochem 174: 255–259

    Article  PubMed  CAS  Google Scholar 

  • Müller T, Büttner T, Gholipour AF, Kuhn W (2003) Coenzyme Q(10) supplementation provides mild symptomatic benefit in patients with Parkinson’s disease. Neurosci Lett 341: 201–204

    Article  PubMed  Google Scholar 

  • Overvad K, Diamant B, Holm L, Holmer G, Mortensen SA, Stender S (1999) Coenzyme Q10 in health and disease. Eur J Clin Nutr 53: 764–770

    Article  PubMed  CAS  Google Scholar 

  • Paulsen JS, Zhao H, Stout JC, Brinkman RR, Guttman M, Ross CA, Como P, Manning C, Hayden MR, Shoulson I (2001) Clinical markers of early disease in persons near onset of Huntington’s disease. Neurology 57: 658–662

    Article  PubMed  CAS  Google Scholar 

  • Penney Jr JB, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH (1997) CAG repeat number governs the development rate of pathology in Huntington’s disease. Ann Neurol 41: 689–692

    Article  PubMed  Google Scholar 

  • Przedborski S, Jackson-Lewis V, Muthane U, Jiang H, Ferreira M, Naini AB, Fahn S (1993) Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 34: 715–723

    Article  PubMed  CAS  Google Scholar 

  • Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, Borchelt DR (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-tenninal fragment of huntingtin. Hum Mol Genet 8: 397–407

    Article  PubMed  CAS  Google Scholar 

  • Shults CW, Haas RH, Passov D, Beal MF (1997) Coenzyme QI0 levels correlate with the activitie s of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol 42: 261–264

    Article  PubMed  CAS  Google Scholar 

  • Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos BL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M (2002) Effects of coenzyme Q( I0) in early Parkinson disease — Evidence of slowing of the functional decline. Arch Neurol 59: 1541–1550

    Article  PubMed  Google Scholar 

  • Smith PR, Cooper JM, Govan GG, Harding AE, Schapira AH (1993) Smoking and mitochondrial function: a model for environmental toxins. Q J Med 86: 657–660

    Article  PubMed  CAS  Google Scholar 

  • Tabrizi SJ, Schapira AHV (1999b) Secondary abnormalities of mitochondrial DNA associated with neurodegeneration. Biochem Soc Symp 66: 99–110

    PubMed  CAS  Google Scholar 

  • Tabrizi SJ, Cooper JM, Xuereb JH, Schapira AHV (1997) Mechanisms involved in the pathogenesis of Huntington’s disease. Ann Neurol 42: T202

    Google Scholar 

  • Tabrizi SJ, Cleeter MWJ, Xuereb J, Taanman JW, Cooper JM, Schapira AHV (1999a) Biochemical abnormalities and excitotoxicity in Huntington’s disease brain. Ann Neurol 45: 25–32

    Article  PubMed  CAS  Google Scholar 

  • Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G, Cooper JM, Schapira AHV (2000) Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol 47: 80–86

    Article  PubMed  CAS  Google Scholar 

  • Tabrizi SJ, Rajagopalan B, Styles P, Manners D, Schapira AH, Warner TT (2002) Creatine therapy for Huntington’s disease (HD): clinical and-(31)phosphorous magnetic resonance spectroscopy (P-31 MRS) findings in a one year pilot. Mov Disord 17: S319

    Google Scholar 

  • Tabrizi SJ, Blamire AM, Manners DN, Rajagopalan B, Styles P, Schapira AHV, Warner TT (2003) Creatine therapy for Huntington’s disease: clinical and MRS findings in a 1-year pilot study. Neurology 61: 141–142

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, D-44791, Bochum, Germany

    J. Andrich, C. Saft, M. Gerlach, B. Schneider, A. Arz, W. Kuhn & Pr. Th. Müller

  2. Department for Child and Youth Psychiatry, Clinical Neurochemistry, Würzburg

    M. Gerlach

  3. Department of Neurology, Leopoldina Krankenhaus, Schweinfurt, Germany

    W. Kuhn

Authors
  1. J. Andrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Saft
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Gerlach
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Arz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W. Kuhn
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pr. Th. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Neurologische Klinik, St. Josef Hospital, Gudrunstraße 56, 44791, Bochum, Germany

    Th. Müller

  2. Klinik und Poliklinik für Psychiatrie und Psychotherapie, Füchsleinstraße 15, 97080, Würzburg, Germany

    P. Riederer

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Wien

About this chapter

Cite this chapter

Andrich, J. et al. (2004). Coenzyme Q10 serum levels in Huntington’s disease. In: Müller, T., Riederer, P. (eds) Focus on Extrapyramidal Dysfunction. Journal of Neural Transmission. Supplementa, vol 68. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0579-5_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-0579-5_13

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-21114-4

  • Online ISBN: 978-3-7091-0579-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation